nach oben

Current Dermatology Reports

Erschienen in:

23.10.2018 | Wound Care and Healing (H Lev-Tov, Section Editor)

Healing Chronic Wounds: Current Challenges and Potential Solutions

verfasst von: Evan Darwin, Marjana Tomic-Canic

Erschienen in: Current Dermatology Reports | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to raise awareness, examine the challenges faced by wound care researchers, and explore opportunities for potential improvements.

Recent Findings

Chronic wounds are associated with significant morbidity and mortality, and they represent a major medical and financial burden. Despite this, no new therapy has received FDA efficacy approval for the treatment of chronic wounds since 1997. Previous preclinical studies using animal models did not translate to human wounds due to inherent limitations of experimental models, variability in assessment methods, and overall experimental design. Clinical trials continued to be challenged by the balance of the inclusion and exclusion criteria, the high cost and time expenditure of the trials, and the constraint of a single FDA-acceptable outcome of complete wound closure.

Summary

Wound research faces multiple challenges in both preclinical and clinical research that slowed progress and development of efficacious therapies. Solutions to such challenges will provide new opportunities for improved study design in the future.

Lim HW, Collins SAB, Resneck JS Jr, Bolognia JL, Hodge JA, Rohrer TA, et al. The burden of skin disease in the United States. J Am Acad Dermatol. 2017;76(5):958–72.e2. https://doi.org/10.1016/j.jaad.2016.12.043.CrossRefPubMed

Armstrong DG, Wrobel J, Robbins JM. Guest editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J. 2007;4(4):286–7. https://doi.org/10.1111/j.1742-481X.2007.00392.x.CrossRefPubMed

Moffatt CJ, Franks PJ, Doherty DC, Smithdale R, Steptoe A. Psychological factors in leg ulceration: a case-control study. Br J Dermatol. 2009;161(4):750–6. https://doi.org/10.1111/j.1365-2133.2009.09211.x.CrossRefPubMed

de Jesus Pereira MT, Magela Salome G, Guimaraes Openheimer D, Cunha Esposito VH, Aguinaldo de Almeida S, Masako Ferreira L. Feelings of powerlessness in patients with diabetic foot ulcers. Wounds. 2014;26(6):172–7.PubMed

Gibson S, Green J. Review of patients’ experiences with fungating wounds and associated quality of life. J Wound Care. 2013;22(5):265–6, 8, 70–2, passim. https://doi.org/10.12968/jowc.2013.22.5.265.CrossRefPubMed

Jones J, Barr W, Robinson J, Carlisle C. Depression in patients with chronic venous ulceration. Br J Nurs (Mark Allen Publishing). 2006;15(11):S17–23. https://doi.org/10.12968/bjon.2006.15.Sup2.21237.CrossRef

Jones JE, Robinson J, Barr W, Carlisle C. Impact of exudate and odour from chronic venous leg ulceration. Nurs Stand (Royal College of Nursing (Great Britain) : 1987). 2008;22(45):53–4, 6, 8 passim. https://doi.org/10.7748/ns2008.07.22.45.53.c6592.CrossRef

Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N. Burden of venous leg ulcers in the United States. J Med Econ. 2014;17(5):347–56. https://doi.org/10.3111/13696998.2014.903258.CrossRefPubMed

trials.gov c. clinical trials.gov. U.S. Natioanl Library of medicine. 2018. https://clinicaltrials.gov/ct2/results?cond=venous+leg+ulcer&term=&cntry=&state=&city=&dist=. Accessed 4/16/2018 2018.

10.

Eaglstein WH, Kirsner RS, Robson MC. Food and Drug Administration (FDA) drug approval end points for chronic cutaneous ulcer studies. Wound Repair Regen. 2012;20(6):793–6. https://doi.org/10.1111/j.1524-475X.2012.00849.x.CrossRefPubMed

11.

Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16(5):585–601. https://doi.org/10.1111/j.1524-475X.2008.00410.x.CrossRefPubMed

12.

Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M. Keratins and the keratinocyte activation cycle. J Invest Dermatol. 2001;116(5):633–40. https://doi.org/10.1046/j.0022-202x.2001.doc.x.CrossRefPubMed

13.

Martin P, Nunan R. Cellular and molecular mechanisms of repair in acute and chronic wound healing. Br J Dermatol. 2015;173(2):370–8. https://doi.org/10.1111/bjd.13954.CrossRefPubMedPubMedCentral

14.

Loots MA, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middelkoop E. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol. 1998;111(5):850–7. https://doi.org/10.1046/j.1523-1747.1998.00381.x.CrossRefPubMed

15.

Stojadinovic O, Pastar I, Vukelic S, Mahoney MG, Brennan D, Krzyzanowska A, et al. Deregulation of keratinocyte differentiation and activation: a hallmark of venous ulcers. J Cell Mol Med. 2008;12(6b):2675–90. https://doi.org/10.1111/j.1582-4934.2008.00321.x.CrossRefPubMedPubMedCentral

16.

Brem H, Stojadinovic O, Diegelmann RF, Entero H, Lee B, Pastar I, et al. Molecular markers in patients with chronic wounds to guide surgical debridement. Mol Med (Cambridge, Mass). 2007;13(1–2):30–9. https://doi.org/10.2119/2006-00054.Brem.CrossRef

17.

Pastar I, Stojadinovic O, Krzyzanowska A, Barrientos S, Stuelten C, Zimmerman K, et al. Attenuation of the transforming growth factor beta-signaling pathway in chronic venous ulcers. Mol Med (Cambridge, Mass). 2010;16(3–4):92–101. https://doi.org/10.2119/molmed.2009.00149.CrossRef

18.

Pastar I, Wong LL, Egger AN, Tomic-Canic M. Descriptive vs mechanistic scientific approach to study wound healing and its inhibition: is there a value of translational research involving human subjects? Exp Dermatol. 2018;27(5):551–62. https://doi.org/10.1111/exd.13663.CrossRefPubMed

19. •

Eming SA, Martin P, Tomic-Canic M. Wound repair and regeneration: mechanisms, signaling, and translation. Science translational medicine. 2014;6(265):265sr6. https://doi.org/10.1126/scitranslmed.3009337. Highlights the biologic underpinnings of wound healing and explains the various animal models used in basic science (model organisms), pre-c;inical testing and discussess clinical wound healing trials. CrossRef

20.

Franklin JD, Lynch JB. Effects of topical applications of epidermal growth factor on wound healing. Experimental study on rabbit ears. Plast Reconstr Surg. 1979;64(6):766–70.CrossRef

21.

Pastar I, Stojadinovic O, Tomic-Canic M. Role of keratinocytes in healing of chronic wounds. Surg Technol Int. 2008;17:105–12.PubMed

22.

Nuutila K, Katayama S, Vuola J, Kankuri E. Human wound-healing research: issues and perspectives for studies using wide-scale analytic platforms. Adv Wound Care. 2014;3(3):264–71. https://doi.org/10.1089/wound.2013.0502.CrossRef

23.

Sullivan TP, Eaglstein WH, Davis SC, Mertz P. The pig as a model for human wound healing. Wound Repair Regen. 2001;9(2):66–76.CrossRef

24.

Montagna W, Yun JS. The skin of the domestic pig. J Invest Dermatol. 1964;42:11–21.CrossRef

25.

Seaton M, Hocking A, Gibran NS. Porcine models of cutaneous wound healing. ILAR J. 2015;56(1):127–38. https://doi.org/10.1093/ilar/ilv016.CrossRefPubMed

26.

Elliot S, Wikramanayake TC, Jozic I, Tomic-Canic M. A modeling conundrum: murine models for cutaneous wound healing. J Invest Dermatol. 2018;138(4):736–40. https://doi.org/10.1016/j.jid.2017.12.001.CrossRefPubMed

27.

Ansell DM, Marsh C, Walker L, Hardman MJ, Holden K. Evaluating STZ-induced impaired wound healing in rats. J Invest Dermatol. 2018;138(4):994–7. https://doi.org/10.1016/j.jid.2017.10.020.CrossRefPubMed

28.

Gilliver SC, Emmerson E, Campbell L, Chambon P, Hardman MJ, Ashcroft GS. 17beta-estradiol inhibits wound healing in male mice via estrogen receptor-alpha. Am J Pathol. 2010;176(6):2707–21. https://doi.org/10.2353/ajpath.2010.090432.CrossRefPubMedPubMedCentral

29.

Toraldo G, Bhasin S, Bakhit M, Guo W, Serra C, Safer JD, et al. Topical androgen antagonism promotes cutaneous wound healing without systemic androgen deprivation by blocking beta-catenin nuclear translocation and cross-talk with TGF-beta signaling in keratinocytes. Wound Repair Regen. 2012;20(1):61–73. https://doi.org/10.1111/j.1524-475X.2011.00757.x.CrossRefPubMedPubMedCentral

30.

Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. The accuracy of venous leg ulcer prognostic models in a wound care system. Wound Repair Regen. 2004;12(2):163–8. https://doi.org/10.1111/j.1067-1927.2004.012207.x.CrossRefPubMed

31.

Mulder G, Tallis AJ, Marshall VT, Mozingo D, Phillips L, Pierce GF, et al. Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): results of a phase 1/2 trial. Wound Repair Regen. 2009;17(6):772–9. https://doi.org/10.1111/j.1524-475X.2009.00541.x.CrossRefPubMed

32.

Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998;21(5):822–7.CrossRef

33.

Maderal AD, Vivas AC, Eaglstein WH, Kirsner RS. The FDA and designing clinical trials for chronic cutaneous ulcers. Semin Cell Dev Biol. 2012;23(9):993–9. https://doi.org/10.1016/j.semcdb.2012.09.014.CrossRefPubMed

34.

Lamb KA, Backhouse MR, Adderley UJ. A qualitative study of factors impacting upon the recruitment of participants to research studies in wound care - the community nurses’ perspective. J Tissue Viability. 2016;25(3):185–8. https://doi.org/10.1016/j.jtv.2016.03.004.CrossRefPubMed

35.•

U.S Department of Health and Human Services. Guidance for Industry: Chronic Cutaneous Ulcer and Burn Wounds – Developing Products for Treatment. In: Food and Drug Administration. 2006. https://www.fda.gov/downloads/drugs/guidances/ucm071324.pdf. Accessed 1 May 2018. Current FDA guidelines for wound healing trials.

36.•

Driver VR, Gould LJ, Dotson P, Gibbons GW, Li WW, Ennis WJ et al. Identification and content validation of wound therapy clinical endpoints relevant to clinical practice and patient values for FDA approval. Part 1. Survey of the wound care community. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 2017;25(3):454–65. https://doi.org/10.1111/wrr.12533. A collaboration between the FDA and two major wound healing organisations American Association of Wound Care (AAWC) and the Wound Healing Society (WHS) and wound researchers to identify potentential new primary endpoints for clinical trials testing potential therapies. CrossRef

37.

Robson MC, Phillips LG, Thomason A, Altrock BW, Pence PC, Heggers JP, et al. Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers. Ann Plast Surg. 1992;29(3):193–201.CrossRef

38.

Robson MC, Phillips TJ, Falanga V, Odenheimer DJ, Parish LC, Jensen JL, et al. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen. 2001;9(5):347–52.CrossRef

39.

Schaper NC, Apelqvist J, Bakker K. Reducing lower leg amputations in diabetes: a challenge for patients, healthcare providers and the healthcare system. Diabetologia. 2012;55(7):1869–72. https://doi.org/10.1007/s00125-012-2588-z.CrossRefPubMedPubMedCentral

40.

Sully BG, Julious SA, Nicholl J. A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. Trials. 2013;14:166. https://doi.org/10.1186/1745-6215-14-166.CrossRefPubMedPubMedCentral

41.

Figueroa-Magalhães MC, Jelovac D, Connolly R, Wolff AC. Treatment of HER2-positive breast cancer. Breast (Edinburgh, Scotland). 2014;23(2):128–36. https://doi.org/10.1016/j.breast.2013.11.011.CrossRef

42.

Lindley LE, Stojadinovic O, Pastar I, Tomic-Canic M. Biology and biomarkers for wound healing. Plast Reconstr Surg. 2016;138(3 Suppl):18s–28s. https://doi.org/10.1097/prs.0000000000002682.CrossRefPubMedPubMedCentral

43.

Gibson DJ, Schultz GS. Molecular wound assessments: matrix metalloproteinases. Adv Wound Care. 2013;2(1):18–23. https://doi.org/10.1089/wound.2011.0359.CrossRef

Titel: Healing Chronic Wounds: Current Challenges and Potential Solutions
verfasst von: Evan Darwin
Marjana Tomic-Canic
Publikationsdatum: 23.10.2018
Verlag: Springer US
Erschienen in: Current Dermatology Reports / Ausgabe 4/2018
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-018-0239-4

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Updates on Immunotherapy for the Treatment of Skin Cancer

Skin Barrier Function and Atopic Dermatitis

Dermatologic Reactions to Novel Immune Checkpoint Inhibitors

The Skin Microbiome in Atopic Dermatitis—a Potential Treatment Target?

Use of Lasers in Wound Healing: How to Best Utilize Laser Technology to Prevent Scar Formation

Dress for Success: a Review of Dressings and Wound Care in Hidradenitis Suppurativa